Colorectal CancerNCT07778628
WT1 in Colorectal Adenocarcinoma
An observational study of Colorectal Cancer, run by Sohag University at 1 site in Egypt.
Trial summary
Colorectal carcinoma is a major bublic health problem. It is due to several genetic mutations. Wilms' tumor1 (WT1) gene is a tumor suppressor gene that has been mutated in several human tumors. Detection of WT1 in colorectal carcinoma may provide better future results. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Colorectal Cancer
- What is being tested?
- immunohistochemical staining with WT1 antibody
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Jan 2022to 30 Jun 2026
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: a retrospective, observational study.
Who may be able to join
- patients with colorectal adenocarcinoma.
Who cannot join
- patients who received pre-operative neoadjuvant therapy.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Significance of Immunohistochemical Expression of Wilms' Tumor 1 (WT1) in Colorectal Adenocarcinoma
Colorectal carcinoma is a major bublic health problem. It is due to several genetic mutations. Wilms' tumor1 (WT1) gene is a tumor suppressor gene that has been mutated in several human tumors. Detection of WT1 in colorectal carcinoma may provide better future results.
Read the detailed description
Colorectal adenocarcinoma represents one third of human caners worldwide. It results from cumulative genetic mutations. the incidence of colorectal carcinoma is rising, so, detecting new therapeutic modalities is important. Wilms' Tumor 1 (WT1) gene is a tumor suppressor gene. in certain tumors; WT1 acts as an oncogene, facilitating tumor growth and spread. WT1 is also involved in angiogenesis. we decided to detect expression of WT1 in 60 patients with colorectal adenocarcinoma and detect any association between WT1 expression and certain tumor oarameters as perineural invasion, lymphovascular invasion, lymph node metastasis.
- Conditions
- Colorectal Cancer
- Being tested
- immunohistochemical staining with WT1 antibody
- Keywords
- Wilms' tumor 1, Cancer colon, Angiogenesis, Immunohistochemistry
- Medical subject headings
- Colorectal Neoplasms, Wilms Tumor, Colonic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
immunohistochemical staining with WT1 antibodyBiological
4 micrometer thick tissue sections will be stained by anti humal WT1 immunohistochemical antibody.
| Study group | Role | What they receive |
|---|---|---|
| 60 cases of colorectal carcinoma | 60 formalin fixed, paraffin embedded tissue blocks belonged to patients with colorectal cancer. sections will be obtained and stained immunohistochemically with anti WT1 antibody. Receives: Biological: immunohistochemical staining with WT1 antibody |
What is being measured
The primary outcome is the main question the study is designed to answer.
detection of WT1 in colorectal adenocarcinoma
detection of WT1 in colorectal adenocarcinoma and correlate its expression in tumor cells with certain parameters as patients ages, sexes, tumor grade, lymph node metastasis, lymphovascular invasion and perineural invasion.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2026
- Study start15 Jan 2022
- Primary completion15 Dec 2025
- Study completion30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 60 participants (actual)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Maisa Hashem Mohammed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07778628
- Sponsor's protocol ID
- Soh-Med-26-8-13PD
- Status last verified
- Aug 2026
- First submitted
- 18 Aug 2026
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Significance of Immunohistochemical Expression of Wilms' Tumor 1 (WT1) in Colorectal Adenocarcinoma
- ClinicalTrials.gov ID
- NCT07778628
- Acronym / sponsor ID
- Soh-Med-26-8-13PD
- Conditions
- Colorectal Cancer
- Keywords
- Wilms' tumor 1, Cancer colon, Angiogenesis, Immunohistochemistry
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 15 Jan 2022 (actual)
- Primary completion
- 15 Dec 2025 (actual)
- Study completion
- 30 Jun 2026 (actual)
- First posted
- 21 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Colorectal carcinoma is a major bublic health problem. It is due to several genetic mutations. Wilms' tumor1 (WT1) gene is a tumor suppressor gene that has been mutated in several human tumors. Detection of WT1 in colorectal carcinoma may provide better future results.
Detailed description
Colorectal adenocarcinoma represents one third of human caners worldwide. It results from cumulative genetic mutations. the incidence of colorectal carcinoma is rising, so, detecting new therapeutic modalities is important. Wilms' Tumor 1 (WT1) gene is a tumor suppressor gene. in certain tumors; WT1 acts as an oncogene, facilitating tumor growth and spread. WT1 is also involved in angiogenesis. we decided to detect expression of WT1 in 60 patients with colorectal adenocarcinoma and detect any association between WT1 expression and certain tumor oarameters as perineural invasion, lymphovascular invasion, lymph node metastasis.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Target follow-up
- 6 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 60 cases of colorectal carcinoma | – | Biological: immunohistochemical staining with WT1 antibody60 formalin fixed, paraffin embedded tissue blocks belonged to patients with colorectal cancer. sections will be obtained and stained immunohistochemically with anti WT1 antibody. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- a retrospective, observational study.
Key inclusion criteria (1 listed)
- patients with colorectal adenocarcinoma.
Key exclusion criteria (1 listed)
- patients who received pre-operative neoadjuvant therapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| immunohistochemical staining with WT1 antibody4 micrometer thick tissue sections will be stained by anti humal WT1 immunohistochemical antibody. | Biological | 60 cases of colorectal carcinoma |
Primary outcome
detection of WT1 in colorectal adenocarcinoma
Time frame: 6 months
detection of WT1 in colorectal adenocarcinoma and correlate its expression in tumor cells with certain parameters as patients ages, sexes, tumor grade, lymph node metastasis, lymphovascular invasion and perineural invasion.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
detection of WT1 in colorectal adenocarcinoma (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.